Topics

Glioblastoma | Treatment | Clinical trials | Ipatasertib

Home > Publications > Topics > Glioblastoma > Treatment > Clinical trials > Ipatasertib

Tiu C, Yau W, Silva D, Waldron N, Ameratunga M, Scaranti M, Biondo A, Welsh L, Creak A, Jones TL, Martin AJ, Bridges L, Zachariou A, Crespo M, Ferreira A, Riisnaes R, Gurel B, Figueiredo I, Bogdan D, Yuan W, Morilla R, Swales K, Decordova S, Prout T, Parmar M, Baikady B, Rata M, Blackledge M, Tunariu N, Benjamin P, Rich P, Daly R, Hu X, Yap C, Vivanco I, Paschalis A, Sharp A, Banerji U, Minchom A, de Bono J, Lopez J.
Phase I trial of Ipatasertib plus Atezolizumab enhances PI3K/AKT pathway immune responses in solid tumors and refractory glioblastoma.
Clin Cancer Res. 2026 Apr 27. doi: 10.1158/1078-0432.CCR-25-4364. PMID: 42043781. Trial registration ID: NCT03673787. ˍ